Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway, has been shown to be effective in treating various diseases, including cancer, diabetes, and neurological disorders. The mTOR pathway is a master regulator of cell growth and metabolism, and its dysregulation is implicated in numerous human diseases. Rapamycin forms a complex with FKBP12, an allosteric inhibitor of mTORC1, and inhibits its activity. While rapamycin is effective in inhibiting mTORC1, long-term exposure can also inhibit mTORC2 in some cell types. mTORC1 is involved in cell growth, proliferation, and metabolism, and its dysregulation is linked to cancer and other diseases. mTORC2 is involved in cell survival and cytoskeleton organization. Rapamycin has been shown to inhibit tumor growth in various cancers, including renal cancer, neuroendocrine tumors, and lymphangioleiomyomatosis (LAM). However, its clinical success is limited due to its inability to completely block mTORC1 signaling and the presence of feedback loops that can re-activate upstream signaling pathways. Combination therapy with rapamycin or rapalogs has shown promise in improving drug efficacy and delaying resistance. Rapamycin has also been shown to have beneficial effects on aging and age-related diseases, extending lifespan in mice. However, its use is associated with potential side effects, including impaired wound healing and nephrotoxicity. Rapamycin has also been shown to have beneficial effects on metabolism, including improving insulin sensitivity and reducing obesity. However, it can also cause glucose intolerance and hyperlipidemia in some cases. Despite its limitations, rapamycin remains a promising therapeutic option for various diseases, and ongoing research is exploring new strategies to improve its efficacy and safety.Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway, has been shown to be effective in treating various diseases, including cancer, diabetes, and neurological disorders. The mTOR pathway is a master regulator of cell growth and metabolism, and its dysregulation is implicated in numerous human diseases. Rapamycin forms a complex with FKBP12, an allosteric inhibitor of mTORC1, and inhibits its activity. While rapamycin is effective in inhibiting mTORC1, long-term exposure can also inhibit mTORC2 in some cell types. mTORC1 is involved in cell growth, proliferation, and metabolism, and its dysregulation is linked to cancer and other diseases. mTORC2 is involved in cell survival and cytoskeleton organization. Rapamycin has been shown to inhibit tumor growth in various cancers, including renal cancer, neuroendocrine tumors, and lymphangioleiomyomatosis (LAM). However, its clinical success is limited due to its inability to completely block mTORC1 signaling and the presence of feedback loops that can re-activate upstream signaling pathways. Combination therapy with rapamycin or rapalogs has shown promise in improving drug efficacy and delaying resistance. Rapamycin has also been shown to have beneficial effects on aging and age-related diseases, extending lifespan in mice. However, its use is associated with potential side effects, including impaired wound healing and nephrotoxicity. Rapamycin has also been shown to have beneficial effects on metabolism, including improving insulin sensitivity and reducing obesity. However, it can also cause glucose intolerance and hyperlipidemia in some cases. Despite its limitations, rapamycin remains a promising therapeutic option for various diseases, and ongoing research is exploring new strategies to improve its efficacy and safety.